How can we modify the gut microbiome to treat and prevent #HeartFailure? Great talk by @PetraMamicMD at #HFSA2025 @StanfordCVI

Annual center picture for @CleClinicCIRC ! We turn 3 years old. We’ve accomplished so much in such a short time. Feel blessed working with the many @CleClinicHVTI Staff, scientists, engineers, and students. Thanks to the support @LarsSvenssonMD @tavrkapadia @ClevelandClinic

From the CABANA trial: Patients with #HFpEF benefited even more from #Afib ablation regarding: 🔸Death/CV 🏥 🔸AF recurrence Despite the greater benefit for HFpEF pts, their risk of recurrence remained ⬆️ than in those w/out HFpEF 📎: https://t.co/wxPf72B60o #JACCHF

Official kickoff of #THT2025 with #heartfailure innovations by @BurkhoffMd @TCTMD @HFSA

🚨 Final Call: Secure Your Discounted Room by January 22! Stay at the Omni Boston Hotel at the Seaport, the official #THT2025 venue. Rooms are limited — don’t wait! ✅ Registered attendees, use the reservation link in your confirmation email to secure your spot (subject to

🆕statement on evaluating & managing kidney dysfunction in patients with advanced heart failure. 📷Approach to assessment of kidney dysfunction in advanced HF ✍🏼@nishakidneydoc @WilsonTangMD @RangaswJ @FiedlerAmy @modeldoc @PietermartensMD @JamesCFangMD @CunningBeans @mbakitas

#Perspective: Unraveling the Complex Relationship Between Gut Microbiome and Cardiovascular Diseases @CCLRI @WilsonTangMD https://t.co/oihMAmk7vR

Acetazolamide prevents loop diuretic resistance. #THT2024 @WilfriedMullens @WilsonTangMD

Great start with our fearless leader @BurkhoffMd kicking off exciting #THT2024 with 3 days of packed agenda and exciting discussions in #heartfailure innovations.

Niacin, the B vitamin that was previously used to improve lipid profile and reduce the risk of heart disease, promotes arterial inflammation and cardiovascular risk through its metabolites https://t.co/ZZw51MgO0y @NatureMedicine

The new #JACCHF issue is now out! Hemodynamic gain index and peak rate pressure product can identify patients w/ #HFrEF at risk of poor clinical outcomes. This allows prognostication of #HeartFailure even when CPET is not available. https://t.co/HoRswDCAJe #CHF @WilsonTangMD

So incredibly proud of @ClevelandClinic representation at #CMR2024 in London @SCMRorg. 14 oral presentations and a ECA finalist. Celebrating at last night’s dinner! @ATandonMD @DebbieKwonMD @CleClinicCIRC @CleClinicHVTI @CleClinicLCM

The MF is thrilled to announce one of the 2023 Fellowship Grant recipients, Dr. Simon Vanhentenrijk, MD, Pharm D, of the Cleveland Clinic! Read about his work below. https://t.co/bJRgkUzYCF

Q: Is intravenous iron beneficial for patients with #heartfailure and iron deficiency? A: In patients with HF and iron deficiency, treatment with IV iron can reduce CV deaths and HF hospitalizations. https://t.co/sMG36A0Vtw #JACCHF

#CVCT2023 #JACCHF SimPub: Meta-analysis of all randomized controlled trials in #HeartFailure. IV iron reduces both CV-death and HF-readmissions. But it might be time to redefine our definition of iron deficiency based on TSAT. https://t.co/YJAAVeVPiO @CVCTForum @PieterMartensMD

🚨 Act Fast! 🕒 Deadlines for #THT2024 Call for Science are right around the corner! 👉 Submit abstracts, fellows abstracts, fellows challenging cases, and THT Shark Tank Innovation Competition by Dec. 4, 2PM ET. 👉 Submit late-breaking clinical science/first-in-human and early

Prognostic Value of Natriuretic Peptide Levels for Adverse Renal Outcomes in Patients With Moderate to Severe Acute Kidney Injury With or Without Heart Failure. #AHAJournals @WilsonTangMD https://t.co/iP9LPOPlbh

News in EHJ: Promises and challenges of targeting anti-CXCR3 autoantibodies in cardiovascular disease! https://t.co/99mtq8h7Ld #cardioprotective #therapy #autoantibodies #G-protein #receptors #cardiotwitter @escardio @ESC_journals

This phase 3 trial of patisiran, a small interfering RNA that targets hepatic production of the transthyretin protein, showed efficacy in treating transthyretin-mediated (ATTR) cardiac amyloidosis. Read the full APOLLO-B trial results:

Emerging insights into the pathophysiologic basis, mode action and proof of concept features of renal assist devices in acute decompensated heart failure: https://t.co/QvEwqiS8g7 #JACCHF #HeartFailure @PieterMartensMD @WilsonTangMD